Tobam Has $685,000 Holdings in DaVita Inc. (NYSE:DVA)

Tobam cut its stake in DaVita Inc. (NYSE:DVA - Free Report) by 70.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,475 shares of the company's stock after selling 10,654 shares during the period. Tobam's holdings in DaVita were worth $685,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DVA. Yousif Capital Management LLC lifted its holdings in shares of DaVita by 22.1% during the 4th quarter. Yousif Capital Management LLC now owns 10,362 shares of the company's stock worth $1,550,000 after acquiring an additional 1,877 shares during the period. Choreo LLC lifted its holdings in shares of DaVita by 20.1% during the 4th quarter. Choreo LLC now owns 1,706 shares of the company's stock worth $256,000 after acquiring an additional 285 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of DaVita during the 4th quarter worth about $597,000. Strategic Financial Concepts LLC bought a new position in shares of DaVita during the 4th quarter worth about $9,371,000. Finally, Sanctuary Advisors LLC bought a new position in shares of DaVita during the 4th quarter worth about $180,000. 90.12% of the stock is owned by institutional investors.

DaVita Price Performance

Shares of DaVita stock traded up $1.71 during mid-day trading on Monday, reaching $137.83. 646,704 shares of the stock were exchanged, compared to its average volume of 822,086. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The company has a market cap of $10.41 billion, a price-to-earnings ratio of 12.83, a price-to-earnings-growth ratio of 1.07 and a beta of 1.11. DaVita Inc. has a fifty-two week low of $131.76 and a fifty-two week high of $179.60. The firm has a 50-day simple moving average of $141.25 and a 200 day simple moving average of $150.78.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, beating the consensus estimate of $1.75 by $0.25. The firm had revenue of $3.22 billion during the quarter, compared to analysts' expectations of $3.22 billion. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The company's quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the company posted $2.26 EPS. On average, sell-side analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on DVA shares. Barclays raised their price objective on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. Truist Financial dropped their target price on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research report on Monday, May 19th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research report on Friday, February 21st. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Finally, Cowen reiterated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $164.50.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.